10x Genomics
266 hedge funds and large institutions have $3.19B invested in 10x Genomics in 2022 Q4 according to their latest regulatory filings, with 66 funds opening new positions, 75 increasing their positions, 87 reducing their positions, and 28 closing their positions.
136% more first-time investments, than exits
New positions opened: 66 | Existing positions closed: 28
30% more capital invested
Capital invested by funds: $2.45B → $3.19B (+$744M)
14% more funds holding
Funds holding: 233 → 266 (+33)
1.08% more ownership
Funds ownership: 90.55% → 91.63% (+1.1%)
10% more call options, than puts
Call options by funds: $42.7M | Put options by funds: $38.9M
14% less repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 87
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$36.3M |
| 2 |
Millennium Management
New York
|
+$32.7M |
| 3 |
Wolverine Trading
Chicago,
Illinois
|
+$30.7M |
| 4 |
Man Group
London,
United Kingdom
|
+$17.8M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$16.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.7M |
| 2 |
AAM
Ardevora Asset Management
London,
United Kingdom
|
-$15.5M |
| 3 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$12.9M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$11M |
| 5 |
BAMCO Inc
New York
|
-$9.67M |
TXG Hedge Fund Activity: Q4 2022 in Review
266 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q4 2022, worth a combined $3.19B — up 30% from $2.45B a quarter earlier.
Buyers outnumbered sellers: 66 funds opened new TXG positions and 28 closed out — a net gain of 38 holders — while 75 added to existing stakes and 87 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $36.3M. The largest seller was Fidelity Investments, cutting an estimated $16.7M.
- 266 institutional investors held 10x Genomics (TXG) as of Q4 2022, up from 233 in Q3 2022.
- Funds reported $3.19B of 10x Genomics stock for Q4 2022, up 30% quarter-over-quarter.
- 66 funds opened new 10x Genomics positions in Q4 2022 and 28 closed out, a net change of +38 holders.
- The largest 10x Genomics buyer in Q4 2022 was Citadel Advisors, an estimated $36.3M added.
- The largest 10x Genomics seller in Q4 2022 was Fidelity Investments, an estimated $16.7M sold.
Based on aggregated 13F filings for Q4 2022.